Suppr超能文献

三种已获许可的抗真菌药物对西班牙曲霉菌临床分离株的体外活性

In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

作者信息

Gomez-Lopez Alicia, Garcia-Effron Guillermo, Mellado Emilia, Monzon Araceli, Rodriguez-Tudela Juan L, Cuenca-Estrella Manuel

机构信息

Unidad de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.

出版信息

Antimicrob Agents Chemother. 2003 Oct;47(10):3085-8. doi: 10.1128/AAC.47.10.3085-3088.2003.

Abstract

The aim of the present study was to identify retrospectively trends in the species distributions and the susceptibility patterns of Aspergillus species causing fungal infections in Spanish medical centers from 2000 to 2002. The susceptibilities of 338 isolates to amphotericin B, itraconazole, and voriconazole were tested. Aspergillus fumigatus was the most common species (54.7%), followed by Aspergillus terreus (14.8%) and Aspergillus flavus (13.9%). Non-A. fumigatus species were encountered in 45.3% of the samples studied. The majority of Aspergillus isolates were obtained from respiratory tract specimens, followed by ear and skin samples. The geometric mean (GM) MIC of amphotericin B was 0.56 micro g/ml, and the amphotericin B MIC was >2 micro g/ml for 16 isolates (4.7%). Nine of them were A. terreus. The GM MIC of itraconazole was 0.37, and the itraconazole MIC was >4 micro g/ml for 12 (3.5%) isolates. The voriconazole MICs were also high for 8 of the 12 strains for which itraconazole MICs were high (voriconazole MIC range, 2 to 8 micro g/ml).

摘要

本研究的目的是回顾性地确定2000年至2002年西班牙医疗中心引起真菌感染的曲霉属菌种分布趋势及其药敏模式。对338株分离菌进行了两性霉素B、伊曲康唑和伏立康唑的药敏试验。烟曲霉是最常见的菌种(54.7%),其次是土曲霉(14.8%)和黄曲霉(13.9%)。在所研究的45.3%的样本中发现了非烟曲霉菌种。大多数曲霉分离菌来自呼吸道标本,其次是耳部和皮肤样本。两性霉素B的几何平均最低抑菌浓度(GM MIC)为0.56μg/ml,16株分离菌(4.7%)的两性霉素B最低抑菌浓度>2μg/ml。其中9株为土曲霉。伊曲康唑的GM MIC为0.37,12株(3.5%)分离菌的伊曲康唑最低抑菌浓度>4μg/ml。在伊曲康唑最低抑菌浓度高的12株菌株中,有8株的伏立康唑最低抑菌浓度也很高(伏立康唑最低抑菌浓度范围为2至8μg/ml)。

相似文献

1
In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
Antimicrob Agents Chemother. 2003 Oct;47(10):3085-8. doi: 10.1128/AAC.47.10.3085-3088.2003.
7
In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Diagn Microbiol Infect Dis. 1999 Jan;33(1):7-11. doi: 10.1016/s0732-8893(98)00102-3.

引用本文的文献

1
Antifungal Resistance in Non-fumigatus Aspergillus Species.
Mycoses. 2025 Apr;68(4):e70051. doi: 10.1111/myc.70051.
2
Amphotericin B Resistant spp.: Report of Two Cases.
Infect Dis Clin Microbiol. 2024 Dec 19;6(4):343-348. doi: 10.36519/idcm.2024.371. eCollection 2024 Dec.
3
Epidemiology and antifungal susceptibilities of clinically isolated species in South China.
Epidemiol Infect. 2023 Oct 17;151:e184. doi: 10.1017/S095026882300167X.
4
Understanding the environmental drivers of clinical azole resistance in species.
Drug Target Insights. 2022 Nov 22;16:25-35. doi: 10.33393/dti.2022.2476. eCollection 2022 Jan-Dec.
6
Species in Lower Respiratory Tract of Hospitalized Patients from Shanghai, China: Species Diversity and Emerging Azole Resistance.
Infect Drug Resist. 2020 Dec 29;13:4663-4672. doi: 10.2147/IDR.S281288. eCollection 2020.
9

本文引用的文献

4
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.
Clin Infect Dis. 2002 Apr 1;34(7):909-17. doi: 10.1086/339202. Epub 2002 Feb 26.
5
Azole cross-resistance in Aspergillus fumigatus.
Antimicrob Agents Chemother. 2002 Feb;46(2):556-7. doi: 10.1128/AAC.46.2.556-557.2002.
6
Uncommon opportunistic fungi: new nosocomial threats.
Clin Microbiol Infect. 2001;7 Suppl 2:8-24. doi: 10.1111/j.1469-0691.2001.tb00005.x.
9
Antifungal drug resistance in Aspergillus.
J Infect. 2000 Nov;41(3):203-20. doi: 10.1053/jinf.2000.0747.
10
Aspergillus Fumigatus antigen detection in sera from patients at risk for invasive aspergillosis.
J Clin Microbiol. 2000 Jan;38(1):438-43. doi: 10.1128/JCM.38.1.438-443.2000.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验